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Background: The pathogenesis of systemic lupus erythematosus (SLE) has not yet been completely elucidated.
One of the hallmarks of SLE is the production of autoantibodies by uncontrolled over-activated B cells. Early B cell
factor 1 (EBF1) contributes to the development, activation, and proliferation of B cells through activation of the AKT
signaling pathway. Accumulating evidence has demonstrated that several microRNAs (miRNAs) contribute to the
pathogenesis of autoimmune diseases through the regulation of B cells in SLE. We aim to investigate the expression
patterns of miR-1246 in B cells and its contribution to pathogenesis of SLE.
Results: Our results showed that the expression of miR-1246 was significantly decreased in B cells from SLE
patients. We verified that miR-1246 specifically targeted the EBF1 messenger RNA (mRNA) by interacting with its
3′-untranslated region (3′-UTR) and regulated the expression of EBF1. Transfection of miR-1246 inhibitors into
healthy B cells upregulated the expression of EBF1, enhanced B cell function, and increased the production of B cell
surface co-stimulatory molecules CD40, CD80, and CD86. We also observed that abnormal activation of the AKT
signaling pathway was associated with decreased P53 expression, leading to the downregulation of the miR-1246
expression; and upregulation of the miR-1246 expression reversed the responsiveness of B cells by inhibiting EBF1
expression.
Conclusions: Activated B cells in lupus could decrease the expression of miR-1246 through the AKT-P53 signaling
pathway, which in turn enhances the expression of EBF1, thereby promoting further activation of B cells. Conversely,
upregulation of miR-1246 could interrupt this amplification pathway. Our findings thus provide a theoretical
framework towards the research of novel biological targets in SLE treatment.
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Systemic lupus erythematosus (SLE) is a clinically heteroge-
neous autoimmune disease which affects multiple organ
systems and causes significant morbidity and mortality [1].
One of the hallmarks of SLE is the production of anti-
nuclear autoantibodies by uncontrolled over-activated B
cells [2]. The autoantibody-autoantigen immune complexes
deposit in different tissues and organs, leading to chronic
inflammation and tissue damage in many parts of the body.* Correspondence: qianlu5860@gmail.com
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unless otherwise stated.Complicated interactions between genes, environment, hor-
mones, smoking, infections, drugs, and abnormalities in the
adaptive immune system all contribute to the onset and
progression of SLE [3,4]. In recent years, studies have
shown that aberrant epigenetic mechanisms also play an
important role in the pathogenesis of SLE [5-8].
MicroRNA (miRNA), consisting of approximately 19 to
25 nucleotides [9], is one of the principal epigenetic regula-
tory mechanisms which has been identified as a large, novel
sub-class of endogenous noncoding RNAs (ncRNAs). MiR-
NAs can regulate post-transcription of protein-coding
genes by guiding a protein complex known as the RNA-
induced silencing complex (RISC) to bind to the 3′-is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(mRNAs) [10]. This inhibits protein translation and pro-
motes mRNA degradation [11-13]. Current estimates sug-
gest that through this post-transcriptional gene silencing,
miRNAs can regulate at least 60% of human protein-
coding genes [14]. Moreover, recent studies have shown
that miRNAs plays a central role in the regulation, develop-
ment, and function of the immune system and could
potentially serve as disease biomarkers and therapeutic tar-
gets [9,15,16]. It has been reported that several miRNAs,
including miR-155 [17], miR-146a [18], miR-326 [19], miR-
23b [20], miR-126 [21], miR-142-3p/5p [22], miR-182 [23],
miR-150 [24], and miR-124a [25], could modulate the
pathogenesis of autoimmune diseases such as SLE, rheuma-
toid arthritis, and multiple sclerosis through their effects on
T cells and B cell functions [26]. Nevertheless, the mecha-
nisms by which miRNA dysregulation contributes to the
pathogenesis of autoimmune diseases such as SLE have not
been completely elucidated.
At present, miR-1246 has only been found in the ape
and human genomes. In humans, its gene is located in
chromosome two (2q31.1). Some recent studies have re-
ported an association between aberrant miR-1246 ex-
pression and P53 regulation, thereby explaining its role
in the pathogenesis of cancer and Down’s syndrome
[27,28]. In response to DNA damage, p53 can induce
miR-1246 expression, which then reduces the level of
DYRK1A, a Down’s syndrome-associated protein kinase.
In addition, a p53-miR-1246-DYRK1A-NFAT pathway
has been proposed in cancer pathogenesis. It is also re-
ported that serum miR-1246 had a strong potential to
serve as a novel diagnostic and prognostic biomarker in
esophageal squamous cell carcinoma [29]. However, little
is known with regard to the role of miR-1246 in the
pathogenesis of autoimmune diseases. Previous miRNA
microarray studies by our group revealed that miR-1246
was reduced by approximately half in B cells from SLE
patients compared to healthy controls.
In this study, we confirmed the expression patterns
of miR-1246 by using real-time reverse transcription-
polymerase chain reaction (RT-PCR) and investigated
their involvement in SLE pathogenesis. We verified that
miR-1246 specifically targeted early B cell factor 1
(EBF1) mRNA by interacting with its 3′-UTR. Transfec-
tion of miR-1246 inhibitors into healthy B cells could
upregulate the expression of EBF1, enhance B cell func-
tion, and increase the production of B cell surface co-
stimulatory molecules CD40, CD80, and CD86. On the
contrary, upregulation of miR-1246 expression in over-
activated B cells led to the reduction of the EBF1 level
and downregulation of B cell activity. We also demon-
strated that abnormal activation of the AKT signaling
pathway was associated with decreased P53 expression,
leading to the downregulation of the miR-1246 expressionin SLE, and upregulation of the miR-1246 expression
could reverse the responsiveness of B cells by inhibiting
the EBF1 expression. Therefore, we concluded that active
B cells in SLE patients demonstrated activation of AKT
signaling leading to decreased P53 expression, which then
decreased the expression of miR-1246 and enhanced the
expression of EBF1 which contributed to a further activa-
tion of B cells. Increasing the level of miR-1246 could
break down this pathway which led to aberrant B cell acti-
vation. These findings revealed that under-expression of
miR-1246 might be an important molecular mechanism in
B cell over-activation in SLE.
Results
Decreased miR-1246 expression in SLE B cells
In a previous study, our group conducted a high-throughput
miRNA microarray of the activities of 371 miRNAs isolated
from B cells of healthy controls (n= 11) and active SLE pa-
tients (n = 11). Among the 371 miRNAs, we observed that
the expression level of miR-1246 was reduced by approxi-
mately half in B cells from active SLE patients compared
with healthy controls (Figure 1A, B, C). Growing evidence
has indicated that aberrant miRNA expression in B cells
plays an important role in SLE pathogenesis [16]. In this
study, we confirmed the microarray results through real-
time RT-PCR analysis using samples from an additional 30
active SLE patients, 20 inactive patients, and 20 healthy
controls.
We found that miR-1246 was significantly downregu-
lated in B cells from active SLE patients (Figure 1D). We
also compared the expression of miR-1246 in B cells
between 20 inactive SLE patients and 20 healthy controls
and observed no significant difference (Figure 1D), so we
took the active SLE patients as our objectives. Among the
30 active SLE patients, 19 were being treated with cortico-
steroids, antimalarials, or immunosuppressive agents
(Additional file 1: Table S1). To determine whether drug
treatment accounted for the altered miRNA expression
patterns observed in SLE samples, we compared the miR-
1246 expression in untreated SLE patients and treated pa-
tients. There was no significant difference in the expres-
sion of miR-1246 between the two groups (Figure 1E). In
addition, we treated the active SLE patients’ B cells with
prednisone in vitro and found no effect on the miR-1246
expression (data not shown). Furthermore, we did not ob-
serve any correlation between miR-1246 levels and disease
activity of active SLE patients as assessed by the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI)
(data not shown).
Identification of miR-1246 targeting mRNAs in SLE B cells
According to the TargetScan and miRBase bioinformatic
software, EBF1, which is required for the proliferation,
survival, and signaling of pro-B cells and peripheral B cell
Figure 1 Decreased has-miR-1246 expression in B cells from systemic lupus erythematosus (SLE). (A) High-throughput miRNA microarray of
the activities of 371 miRNAs isolated from B cells of healthy controls (n = 11) and active SLE patients (n = 11). Imbalance of green and red signal
signifies non-equivalent activities. (B) Scatter plot of the results in (A); down-expressed miRNAs in active SLE patient samples are indicated by the green
oval. (C) Fold-change of the six miRNAs was found to differ between SLE and control samples. (D, E) Expression of miR-1246 as measured by miRNA
real-time reverse transcription-polymerase chain reaction (RT-PCR) in B cells from 30 active SLE patients (19 were being treated with corticosteroids,
antimalarials, or immunosuppressive agents and 11 were untreated), 20 inactive SLE patients, and 20 age- and sex-matched healthy control subjects.
Transcript levels were significantly reduced in patients with active SLE, regardless of whether they were receiving concurrent medications, while no
significant difference between healthy controls and inactive SLE patients. Bars in (D, E) show the mean ± SD results in 20 healthy donors, 30 patients
with active SLE, and 20 patients with inactive SLE. All experiments were performed in triplicate. (**P < 0.01).
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is a predicted target of miR-1246. To better understand
the relationship between miR-1246 and EBF1, we plotted
miR-1246 expression levels (measured by real-time RT-
PCR) from individual SLE B cell lysates (n = 30) against
EBF1 protein levels (measured by Western blotting) from
the same samples (Figure 2A, B). In this case, a strong in-
verse correlation was observed (Figure 2C). To explore
whether miR-1246 directly regulates EBF1, we transfected
primary B cells from three healthy donors with a miR-
1246 inhibitor or a control miRNA. Two days after trans-
fection, a 3.45-fold reduction of miR-1246 level was
observed while levels of the unrelated miR-126, miR-142-
3p, and miR-142-5p remained unchanged (Figure 3A),
and the level of EBF1 protein was significantly increased
compared with negative controls (Figure 3B, C). Consist-
ent with this finding, transfection of a miR-1246 mimic
into SLE B cells induced a 3.72-fold upregulation of miR-
1246 expression while those of the unrelated miR-126,
miR-142-3p, and miR-142-5p remained unchanged(Figure 3D) and a significantly decreased level of EBF1
protein (Figure 3E, F).
To determine whether EBF1 is a direct target of miR-
1246, a luciferase assay was performed. We constructed
plasmids containing the firefly luciferase reporter ORF
fused downstream to a segment of the EBF1 3′-UTR con-
taining the wild-type putative miR-1246 binding sequence
(EBF1WT-luciferase) or the equivalent segment contain-
ing three-point mutations in the miR-1246 binding
sequence (EBF1Mut-luciferase) (Figure 3G). The con-
structs were then co-transfected into Jurkat cells together
with the miR-1246 mimic or mimic control, and luciferase
activity was measured 48 h after transfection. EBF1WT-
luciferase activity, but not EBF1Mut-luciferase activity,
was significantly reduced in cells co-transfected with the
miR-1246 mimic (Figure 3H). The results showed that
miR-1246 significantly reduced EBF1WT-luciferase activ-
ity. Collectively, these data provide evidence that down-
regulation of miR-1246 leads to increased EBF1 protein
levels in SLE B cells.
Figure 2 Identification of miR-1246 target mRNAs in systemic lupus erythematosus (SLE) B cells. (A, B) Early B cell factor 1 (EBF1) protein
level in B cells from active SLE patients (n = 30) and healthy controls (n = 20). EBF1 expression was significantly increased in active SLE B cells
compared with that in control B cells. Representative Western blotting and quantitative analysis of the band intensities of control (n = 4) and SLE
(n = 4) samples normalized to β-actin is shown at the bottom. (C) In B cells derived from active patients with SLE, has-miR-1246 transcript levels
were negatively correlated with the levels of EBF1 protein (r = −0.82, P < 0.01, n = 30). (**P < 0.01).
Luo et al. Clinical Epigenetics  (2015) 7:24 Page 4 of 13MiR-1246 represses B cell responsiveness
To determine whether miR-1246 downregulation is suf-
ficient to induce responsiveness of B cells in vitro, we
transfected a miR-1246 inhibitor or an inhibitor control
into B cells isolated from three healthy donors. Cells
were collected after 48 h of treatment. Flow cytometric
analysis was then performed to determine the levels of
CD40, CD80, and CD86 expressed in B cells. Compared
to control-transfected B cells, we observed significantly
increased levels of CD40, CD80, and CD86 in miR-1246-
deficient cells (Figure 4A, B). To explore whether miR-
1246 downregulation is necessary for autoimmune re-
activity in patients with SLE, we transfected primary B
cells from active SLE patients with a miR-1246 mimic or
a control miRNA. The results showed significantly
decreased levels of CD40, CD80, and CD86 in SLE B
cells transfected with the miR-1246 mimic, as compared
to control-transfected cells (Figure 4C, D). The actual
flow cytometry profiles are provided in supplementary
materials (Additional file 2: Figure S1 and S2). Taken
together, these results suggest that downregulated miR-
1246 expression in healthy B cells can increase B cell
function and promote B cell hyperresponsiveness, which
means miR-1246 is a negative regulator of B cell activa-
tion, and that induction of over-expression of miR-1246
in SLE B cells may be a means to reverse B cell
hyperactivity.Relationship between B cell activity and miR-1246
Since B lymphocyte activation can affect the expression of
miRNAs, we explored whether miR-1246 downregulation
in SLE patients is a consequence of B cell hyperactivity by
stimulating healthy control B cells with anti-IgM in the
presence of anti-CD40 or PBS (blank control), then mea-
sured miR-1246 expression by real-time RT-PCR; EBF1
protein level, AKT phosphorylation, and p53 protein
levels by Western blot; and CD40, CD80, and CD86 pro-
tein levels by flow cytometry. Next, we transfected a miR-
1246 mimic or control miRNA into stimulated B cells
from healthy controls, then tested miR-1246 expression
by real-time RT-PCR; EBF1 protein level, AKT phosphor-
ylation, and p53 protein level by Western blot; and CD40,
CD80, and CD86 protein levels by flow cytometry. Fur-
thermore, after stimulation and transfection, B cells were
co-cultured with autologous CD4+T cells at a ratio of 4:1
in 96-well round-bottomed plates. After 24 h, CD40L,
CD28, and CD152 protein levels on CD4+T cells were
measured by flow cytometry. The results showed signifi-
cant downregulation of the miR-1246 expression and p53
protein level and upregulation of the EBF1 expression and
AKT phosphorylation level in stimulated B cells from
healthy control (Figure 5A, B, C). CD40, CD80, and CD86
expression levels were increased in response to the stimu-
lation (Figure 5D, E). The actual flow cytometry profiles
are provided in supplementary materials (Additional file 2:
Figure 3 Verification of miR-1246 target genes. (A-C) The expression levels of miR-1246, miR-126, miR-142-3p, and miR-142-5p (A) and early B
cell factor 1 (EBF1) protein (B, C) were analyzed after transfection with miR-1246 inhibitor or inhibitor control. (D-F) The expression levels of
miR-1246, miR-126, miR-142-3p, miR-142-5p (D), and EBF1 protein (E, F) were analyzed after transfection with the miR-1246 mimic or mimic
control. Bars show the mean ± SD results in three healthy donors or three patients with active SLE. All experiments were performed in triplicate.
The Western blot image is a representative image (n = 3). (G) Schematic representation of the EBF1 luciferase reporter construct is shown. The
sequence of the miR-1246 binding site in the 3′-untranslated region (3′-UTR) of EBF1 (gray box) is shown on the left. Mutated residues are shown
in red. (H) Relative firefly luciferase activity in Jurkat cells co-transfected with an empty vector (mimic control) or an miR-1246 mimic, together
with luciferase reporter constructs containing either a wild-type (WT) or a mutated (Mut) EBF1 3′-UTR are shown. Values in (H) are the mean ± SD
results from three independent experiments. (**P < 0.01).
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expression of miR-1246 and P53 protein were significantly
increased, while EBF1 protein expression and AKT
phosphorylation level were sharply decreased (Figure 6A,
B, C), and CD40, CD80, and CD86 expression were greatly
decreased (Figure 6D, E). The actual flow cytometry pro-
files are provided in supplementary materials (Additional
file 2: Figure S4). After co-culture of miR-1246-mimic-
transfected stimulated B cells with CD4+T cells, expres-
sion of CD40L, CD28, and CD152 were significantly
decreased (Figure 6F, G). The actual flow cytometry pro-
files are provided in supplementary materials (Additional
file 2: Figure S5).
Furthermore, we also investigated the importance of AKT
signaling in the regulation of miR-1246 and P53 expression.We treated normal healthy B cells with anti-IgM and anti-
CD40 antibodies or AKT inhibitor pre-treated + anti-IgM
and anti-CD40 antibodies, respectively. Finally, we observed
significantly increased AKT protein phosphorylation and de-
creased P53 protein and miR-1246 expression in anti-IgM
and anti-CD40 antibodies-treated healthy B cells compared
with PBS-treated healthy B cells (blank control). While we
observed significantly decreased AKT protein phosphoryl-
ation, we also observed increased P53 protein and miR-1246
expression in pre-treated AKT inhibitor + anti-IgM and
anti-CD40 antibodies-treated healthy B cells compared with
anti-IgM and anti-CD40 antibodies-treated healthy B cells
(Figure 7A, B, C). Take all together, these findings indicate
that activated B cell receptor (BCR) signaling may contribute
to B cell AKT signaling activation and inhibition of P53
Figure 4 MiR-1246 represses B cell responsiveness. (A, B) Inhibiting miR-1246 expression in healthy controls’ B cells increases CD40, CD80, and CD86
expression and enhances B cell responsiveness. All panels, normal B cells were transfected with miR-1246 inhibitor or inhibitor control. Transfected cells
were stained with PE-Cy7-conjugated anti-human CD40, FITC-conjugated anti-human CD80, PerCP-Cy5.5-conjugated anti-human CD86, and APC-conjugated
anti-human CD19 and analyzed by flow cytometry, percentage (A), and mean fluorescence intensity (MFI) (B) for CD40, CD80, and CD86 in normal B cells
inhibiting miR-1246 and in inhibitor controls (*P< 0.05). (C, D) Overexpression of miR-1246 in SLE B cells decreases CD40, CD80, and CD86 expression
and reduces B cell responsiveness. All panels, SLE B cells were transfected with miR-1246 mimic or mimic control. Transfected cells were stained with
PE-Cy7-conjugated anti-human CD40, FITC-conjugated anti-human CD80, PerCP-Cy5.5-conjugated anti-human CD86, and APC-conjugated anti-human
CD19 and analyzed by flow cytometry, percentage (C), and MFI (D) for CD40, CD80, and CD86 in SLE B cells overexpressing miR-1246 and in mimic controls
(*P< 0.05). All data represent the mean± SD results of three independent experiments. All experiments were performed in triplicate.
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ing to the overexpression of EBF1 that further activates B
cells. When we upregulate the miR-1246 expression, this
positive feedback loop can be broken thereby inhibiting
further B cell activation. Thus, we concluded that downreg-
ulation of miR-1246 in B cells is not just a consequence of
increased lymphocyte activity, but also a potential cause of
SLE autoimmunity.Figure 5 The relationship between B cell activity and miR-1246. (A) M
anti-CD40 antibodies or PBS (control) in normal B cells. (B, C) Representativ
factor 1 (EBF1) protein level, AKT phosphorylation, and P53 protein level in
and PBS (control). (D, E) Percentage (D) and mean fluorescence intensity (M
anti-IgM, anti-CD40, and PBS (control). Data are presented as the mean ± S
(*P < 0.05; **P < 0.01).Regulation of miR-1246 expression by AKT-P53 signaling
pathway in B cells from SLE patients
In previous studies, we found that miR-1246 was signifi-
cantly downregulated in B cells from SLE patients in
comparison with healthy controls. And we also demon-
strated that stimulation of the BCR signaling pathway
increased AKT phosphorylation level and decreased p53
protein and miR-1246 expression. These data indicateeasurement of miR-1246 level after stimulated with anti-IgM and
e Western blotting results and densitometric analysis for early B cell
normal B cells after stimulated with anti-IgM and anti-CD40 antibodies
FI) (E) of CD40, CD80, and CD86 in normal B cells stimulated with
D of the same experiments performed in three healthy donors.
Figure 6 The relationship between B cell activity and miR-1246. (A-E) MiR-1246 expression (A), early B cell factor 1 (EBF1) protein level, AKT
phosphorylation and P53 protein level (B, C), percentage (D), and mean fluorescence intensity (MFI) (E) of CD40, CD80, and CD86 in stimulated B
cell transfected with miR-1246 mimic and mimic control. CD4+T cells which were isolated from the same healthy control were cultured in RPMI
1640 medium with 10% FBS, 100 U/ml penicillin G, and streptomycin. After stimulation and transfection, B cells were co-cultured with autologous
CD4+T cells at a ratio of 4:1 in 96-well round-bottomed plates. At 24 h, percentage (F) and MFI (G) of CD40L, CD28, and CD152 were measured
by flow cytometry. The Western blot image is a representative image. Data are presented as the mean ± SD of the same experiments performed
in three healthy donors. (*P < 0.05; **P < 0.01).
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stream factor leading to altered miR-1246 expression.
Therefore, in this part, we aim to confirm the dysregula-
tion of the AKT-P53 signaling pathway and whether it
contributes to the downregulation of miR-1246 expression
in SLE B cells. We found that AKT phosphorylation was
markedly increased with no obvious difference in AKT
protein level (Figure 8A,C), while P53 protein level was
markedly downregulated (Figure 8B, D) in B cells from
active SLE patients compared to healthy controls. AKTphosphorylation levels were negatively correlated with p53
protein expression levels (Figure 8E), while p53 protein
levels were positively correlated with miR-1246 expres-
sion levels in B cells from SLE patients (Figure 8F). Fur-
thermore, we also investigated whether inhibition of
AKT signaling could affect miR-1246 and P53 expres-
sion in B cells from active SLE patients. We treated ac-
tive SLE B cells with AKT inhibitor, then we observed
significantly decreased AKT protein phosphorylation
and increased P53 protein and miR-1246 expression in
Figure 7 The relationship between B cell activity and miR-1246. We treated three healthy B cells with PBS, anti-IgM and anti-CD40
antibodies, or AKT inhibitor pre-treated + anti-IgM and anti-CD40 antibodies. (A-C) Increased AKT protein phosphorylation and decreased P53
protein and miR-1246 expression in anti-IgM and anti-CD40 antibodies-treated healthy B cells, compared with PBS-treated healthy B cells.
Decreased AKT protein phosphorylation and increased P53 protein and miR-1246 expression in pre-treated AKT inhibitor + anti-IgM and anti-CD40
antibodies-treated healthy B cells compared with anti-IgM and anti-CD40 antibodies-treated healthy B cells. The Western blot image is a
representative image. Data are presented as the mean ± SD of the same experiments performed in three healthy donors. (*P < 0.05; **P < 0.01).
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blank (PBS-treated) (Figure 9A, B, C). Thus, we con-
clude that reduced miR-1246 levels in B cells of SLE pa-
tients might be due to inhibition of p53 protein
expression by AKT phosphorylation.Figure 8 The regulation of miR-1246 expression by AKT-P53 signaling
patients. (A, B) AKT phosphorylation was markedly increased, but no diffe
sharply downregulated (B, D) in B cells from active SLE patients compared
correlated with P53 protein expression levels (E) while P53 protein levels w
active SLE patients (F). The Western blot images are representative images
donors and 30 active patients with SLE. (*P < 0.05).Discussion
SLE is a potentially lethal systemic autoimmune disease
with multi-organ damage. The intricate clinical manifesta-
tions of SLE could immunologically be attributed to the
loss of self-tolerance and the production of autoantibodiespathway in B cells from systemic lupus erythematosus (SLE)
rence in AKT protein expression (A, C), while P53 protein level was
to healthy controls. AKT phosphorylation levels were negatively
ere positively correlated with miR-1246 expression levels in B cells from
(n = 4). Bars in (C) and (D) show the mean ± SD results in 20 healthy
Figure 9 The regulation of miR-1246 expression by AKT-P53 signaling pathway in B cells from SLE patients. AKT protein phosphorylation,
P53 protein levels, and miR-1246 expression were detected in AKT inhibitor-treated SLE B cells compared with PBS-treated SLE B cells. (A-C) AKT
phosphorylation was markedly decreased, while P53 protein level and miR-1246 expression were sharply upregulated in AKT inhibitor-treated SLE
B cells compared with PBS-treated SLE B cells. The Western blot image is a representative image. Data are presented as the mean ± SD of the
same experiments performed in three active SLE patients. (**P < 0.01).
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microRNAs plays an important role in the pathogenesis of
SLE [8]. In the last decades, several independent profiling
studies on immune-cell-derived or circulating miRNA
expression reported significant differences between SLE
patients and healthy controls, which provides useful infor-
mation for understanding SLE pathogenesis and the devel-
opment of biomarkers for diagnosis, prognosis, and novel
therapeutic targets [16]. And the impact of specific
miRNA-mediated regulation on function of major im-
mune cells, such as T and B lymphocytes, in lupus is also
discussed. For example, defective miR-7 regulation of
PTEN, which regulates normal signaling through the
BCR, contributes to B cell hyperresponsiveness in SLE
[32]. In this study, we screened the expression profile of
microRNAs in B cells from active SLE patients and
healthy controls through microarray. We observed and
validated a significant decrease of miR-1246 expression in
B cells only from active SLE patients, but not in inactive
SLE patients or healthy controls, which implicated a role
of miR-1246 in active SLE and might be developed into a
potential biomarker and a novel therapeutic target of ac-
tive SLE.
Previous studies found that the expression of miR-1246
increased significantly in some solid cancers, such as
colon cancer, hepatocellular carcinoma, pancreatic cancer,
and esophageal squamous cell carcinoma, and might be
used as diagnostic and prognostic biomarkers in these dis-
eases [29,33-35]. The upregulation of miR-1246 could
downregulate the expression levels of its target genes to
mediate the proliferation, invasion, and migration of can-
cer cells [34-36]. However, the role of miR-1246 in auto-
immune diseases has been poorly studied. Our results
demonstrated that the downregulation of miR-1246 in ac-
tive B cells from SLE patients could in turn enhance theresponsiveness of B cells through the upregulation of its
target gene EBF1, which has been identified by luciferase
reporter assay.
EBF1 is a transcriptional factor that has a central role in
the development of B cells. EBF1 persists as homodimers
in solution and when it binds to sequences of promoters
that loosely fit the consensus 5′-CCCNNGGG-3′ [37]. It
is a regulator of B cell lineage specification and commit-
ment and is expressed throughout B cell development up
to the plasma cell stage [38]. In the absence of EBF1, pro-
genitor cells fail to express classical markers of B cells, in-
cluding immunoglobulins [39]. EBF1 was found to be
necessary for B cell maturation, and upregulation of EBF1
in B cells contributes to autoreactivity by activating B cell
functions [40,41]. However, there are few reports about
EBF1 involved in the pathogenesis of SLE. Interactions be-
tween T and B cells depend on engagement of appropriate
B cell co-stimulatory molecules [42]. Among the most
important co-stimulatory molecules are those including
CD40 and CD80/86 which are expressed on antigen-
presenting cells (DC, macrophages, and B cells) [43-45].
CD80, CD86, and CD40 play key roles in the polyclonal B
cell activation [46] upon interaction with CD28, CD152,
and CD40L and, in particularly, enhance IgG secretion
[42,47,48]. In our studies, we found that elevation of the
expression level of miR-1246 in lupus B cells could
decrease the expression of EBF1 causing the downregula-
tion of CD40, CD80, and CD86 which are co-stimulatory
molecules required for full B cell activation and IgG secre-
tion [47,49]. On the contrary, a decrease of the level of
miR-1246 in normal B cells would lead to the upregula-
tion of EBF1 and activation of B cells, which means that
miR-1246 acts as a negative regulator of B cell activation
and a protective factor against SLE. CD40 belongs to the
tumor-necrosis-factor super family. On activation upon
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provides a co-stimulatory signal that induces B cell prolif-
eration and differentiation with subsequent antibody pro-
duction [50]. CD40 also promotes CD80/86 expression
and provides further stimulation signals to T cells [51,16].
CD80/86 belong to the immunoglobulin (Ig) superfamily
(IgSF). Interaction between CD80/86-CD28/CD152 is cru-
cial for T cell activation [46]. Consequently, the stimulated
T cells further signal the B cells to proliferate and differen-
tiate into antibody-producing plasma cells and CD80/
CD86 signaling directly regulates IgG secretion by previ-
ously activated B cells [52].
Activation of phosphoinositide 3-kinase (PI3K) has
been demonstrated to play a pivotal role in B cell prolif-
eration and survival. It initiates a signaling pathway in-
volving a serine-threonine kinase AKT which is essential
for B cell functions and decisions. However, the AKT
signaling pathway has complex roles in B cell fate and
the exact mechanisms remain to be elucidated [53,54]. In
this study, we stimulated normal B cells with anti-IgM
and anti-CD40, and we observed that the expression level
of miR-1246 decreased, whereas EBF1 expression level in-
creased. In addition, the B cells were activated and CD40,
CD80, and CD86 expression levels were upregulated.
Since miR-1246 has been proved to be a target microRNA
of transcriptional factor P53 [27,28] and P53 can be medi-
ated by AKT signaling pathway which plays an important
role in cellular proliferation and growth signaling [55,56],
we examined the levels of miR-1246, pAKT, and the pro-
teins of EBF1, P53, CD40, CD80, and CD86 in activated
normal B cells. The results showed that the protein levels
of EBF1, CD40, CD80, and CD86 and the phosphorylation
level of AKT increased and expression of miR-1246 and
the protein level of P53 decreased. Taken all together, we
hypothesized that activation of B cells could cause the
phosphorylation of AKT which inhibited P53 expression
leading to the downregulation of miR-1246 transcription
and the upregulation of EBF1 which in turn promotes fur-
ther activation of B cells. Moreover, when we transfected
activated normal B cells with miR-1246 mimics, we found
that the protein level of EBF1 and the phosphorylation
level of AKT decreased while the protein level of P53 in-
creased which led to the further elevated expressional
level of miR-1246, causing the decreased expression of
CD40, CD80, and CD86 and an inhibition of B cells acti-
vation. And co-incubation of this transfected B cells with
autologous T cells could reduce the expression of T cell
co-stimulatory molecules CD40L, CD28, and CD152,
which are ligands of CD40, CD80, and CD86 on B cells.
Then, we pretreated normal B cells with AKT inhibitor,
then stimulated them with anti-IgM and anti-CD40 anti-
bodies, and found that the phosphorylation level of AKT
decreased while the protein level of P53 increased which
led to the elevated expressional level of miR-1246compared with anti-IgM- and anti-CD40-treated normal
B cells. These implicated that activation of B cells could
downregulate miR-1246 expression through the AKT-P53
signaling pathway, and decreased miR-1246 could aggra-
vate B cells’ further activation by regulating EBF1, which
means downregulation of miR-1246 in B cells is not just a
consequence of increased lymphocyte activity, but also a
potential cause of autoimmunity.
In the last part of the study, we found increased AKT
phosphorylation while a downregulated P53 protein level
in B cells from active SLE patients compared to healthy
controls. P53 protein expression levels were negatively
correlated with AKT phosphorylation levels and posi-
tively correlated with miR-1246 expression levels in B
cells from active SLE patients. Furthermore, we treated
active SLE B cells with AKT inhibitor and found that the
phosphorylation level of AKT decreased and the protein
level of P53 and miR-1246 expression increased. Yong-
xin Zhou et al. have reported that PI3K/AKT plays an
important role in inhibition of spontaneous B apoptosis
by downregulation of P53 [55]. Yu Zhang et al. investi-
gate that miR-1246 is a new transcriptional target of the
p53 by chromatin-associated immunoprecipitation as-
says, plasmid construction, and luciferase activity assay
[27,28]. Thus, we conclude that since the p53 protein
level is directly correlated with the miR-1246 expression,
reduced miR-1246 levels in B cells of SLE patients may
be due to inhibition of the P53 protein expression by
AKT phosphorylation.
Conclusions
The results from this study demonstrate the mechanistic
relationship between B cell activation in SLE, decreased
miR-1246 expression through AKT-P53 signaling path-
way, and downstream effect on the expression of EBF1
leading to further activation of B cells. Therefore, ther-
apies that turn the expression of affected miR-1246
genes back to normal could serve as a potential and ef-
fective method for treating SLE.
Methods
Samples
All subjects (active SLE patients: n = 30, inactive pa-
tients: n = 20, healthy controls: n = 20) recruited for this
study were under a protocol approved by the Human
Ethics Committee of Second Xiangya Hospital, Central
South University, with an informed written consent. All
SLE patients fulfilled the American College of Rheuma-
tology (ACR) classification criteria for SLE [57]. Disease
activity was assessed by the Systematic Lupus Activity
Measure (SLAM) [58] and Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI) [59] at the time of
blood collection. Patients who had active disease or in-
active disease were selected based on the SLEDAI results
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than 4). Venous blood samples were collected from 30
active SLE patients (all female, age 32.7 ± 11.3 years), 20
inactive SLE patients (all female, age 30.3 ± 9.29 years) at
the out-patient dermatology clinic and in-patient ward
of the Department of Dermatology, the Second Xiangya
Hospital, Central South University, China. Relevant pa-
tient information is listed in Additional file 1: Table S1.
Twenty healthy controls with age and sex matched (all
female, age 30.7 ± 8.6 years) were recruited from staff
and graduate students at the Second Xiangya Hospital.
Cell isolation, cultures, and transfection
A total of 60 ml of venous peripheral blood was with-
drawn from each patient and control subject and pre-
served with heparin. B cells were isolated by positive
selection using CD19 beads, according to protocols pro-
vided by the manufacturer (Miltenyi, BergischGladbach,
Germany; purity was generally higher than 95%) and
cultured in human B cell culture medium (Lonza,
Walkersville, MD, USA) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin. B
Cells were transiently transfected with mimic/inhibitor
control, has-mir-1246 mimic, or has-mir-1246 inhibitor
(Ambion, USA) using Human B cell Nucleofector Kits
and a nucleofector (Amaxa, USA) according to the man-
ufacturer’s instructions. First, B cells were harvested and
resuspended in 100-μl human B cell nucleofector solu-
tion, and then, the cell suspension was mixed with has-
mir-1246 mimic/inhibitor or mimic/inhibitor control.
The mix was electrotransfected using nucleofector pro-
gram U-015 in the Amaxa nucleofector. The transfected
cells were cultured in human B cell culture medium and
harvested after 48 h.
RNA isolation and real-time quantitative RT-PCR
Total RNA from B cells was isolated using TRIzol (Invitro-
gen Carlsbad, CA, USA). The relative abundance of gene
expression was determined by real-time PCR using a Rotor-
Gene 3000 (Corbett Research, NSW, Australia). cDNAs
were synthesized from 1 μg of total RNA using the miScript
Reverse Transcription Kit (Qiagen, Germany). DNA was
synthesized from cDNA. Real-time PCR was performed
using the Rotor-Gene 3000 Real-time PCR instrument (Cor-
bett Research, Australia). All reactions were run in triplicate.
Expression levels of target miRNAs were normalized to
RUN6-2 and analyzed with Rotor-Gene Real-Time Analysis
Software 6.0. MiR-1246, miR-126, miR-142-3p, miR-142-5p,
and RUN6-2 primers were ordered from Qiagen. The infor-
mation about the primers used for PCR are listed in
Additional file 1: Table S2. ΔCt was calculated by subtract-
ing the Ct values for RUN6-2 from the Ct value for the gene
of interest. ΔΔCt was calculated by subtracting the con-
trol Ct from SLE Ct. The fold change of expressionbetween control and SLE samples was calculated by the
equation: 2−ΔΔCt.
Plasmid construction and luciferase activity assay
A fragment sequence from the 3′-UTR of EBF1 containing
a putative miRNA binding site was amplified by PCR from
human B cell genomic DNA. The same procedure was used
to generate reporter constructs with mutations in the 3′-
UTR of the target gene. 3′-UTR sequences were inserted
into pMIR-REPORT luciferase miRNA Expression Reporter
Vector (Ambion) using Spe I and Hind III. The primers
used for PCR are listed in Additional file 1: Table S2. Jurkat
cells were cultured in RPMI 1640 with 10% FBS. Luciferase
activity assays were performed as previously described [21]
with 5 μg of firefly luciferase reporter vector containing ei-
ther the wild-type or mutant oligonucleotides, 0.5 μl of
mimic control, and has-mir-1246 mimic. Relative luciferase
activity was normalized to renilla luciferase activity for each
transfected well. Experiments were performed in triplicate
in three independent trials.
B cell activation
Purified B cells from healthy control were cultured in 6-
well plates (1 × 106/ml) and stimulated with anti-IgM
(2 μg/ml) in the presence of anti-CD40 (0.1 μg/ml) and
PBS (blank control), then incubated for 6 h at 37°C.
AKT inhibition
Purified B cells from healthy control were cultured in 6-
well plates (1 × 106/ml) and stimulated with MK-2206
2HC (Selleck Chemicals, TX, USA), a specific AKT inhibi-
tor or PBS (blank control); after being incubated for 6 h,
anti-IgM (2 μg/ml) + anti-CD40 (0.1 μg/ml) were added
into them, then incubated for 6 h at 37°C. Purified B cells
from active SLE patients were cultured in 6-well plates
(1 × 106/ml) and stimulated with AKT inhibitor or PBS
(blank control), then incubated for 6 h at 37°C.
Western blot analysis
B cells were lysed in protein lysis buffer containing phos-
phatase inhibitor (Therm Pierce). Lysates were centrifuged
for 15 min at 14,000 × g at 4°C, and protein concentration
was determined by Bradford protein assay (Bio-Rad, CA,
USA). Proteins were separated by SDS-PAGE using 8%
polyacrylamide gels. Proteins were then transferred onto
PVDF membranes (Millipore, MA, USA). Membranes
were blocked with 5% non-fat dry milk in Tris-buffered
saline containing 0.1% Tween-20 (TBST) buffer and
immunoblotted with primary antibodies including anti-β-
actin (Sigma, MA, USA), anti-EBF1 (Sigma, MA, USA),
anti-AKT (Sigma, MA, USA), anti-pAKT (Sigma, MA,
USA), and anti-P53 (Sigma, MA, USA). Band intensity
was quantified using Quantity One software (Bio-Rad,
CA, USA).
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PE-Cy7-conjugated anti-human CD40, FITC-conjugated
anti-human CD80, PerCP-Cy5.5-conjugated anti-human
CD86, PE-Cy5-conjugated anti-human CD40L, APC-
conjugated anti-human CD28, PE-conjugated anti-human
CD152, APC-conjugated anti-human CD19, and FITC-
conjugated anti-human CD4 were purchased from Becton
Dickinson (USA). Data were acquired using a FACScalibur
system (Becton Dickinson) and analyzed using CellQuest
software (Becton Dickinson,).
T-B cell co-cultures for conjugate and co-stimulation
assays
Isolated normal CD4+T cells were cultured in RPMI 1640
medium with 10% FBS, 100 U/ml of penicillin G, and
streptomycin. After stimulation with anti-IgM (2 μg/ml)
in the presence of anti-CD40 (0.1 μg/ml), for 6 h, CD40,
CD80, and CD86 were measured from partially stimulated
B cells by flow cytometry with the cells stained at 4°C for
anti-CD40, anti-CD80, anti-CD86, and anti-CD19 anti-
bodies. Stimulated B cells were transfected with miR-1246
mimic or a mimic control, for 48 h, and then, treated B
cells were co-cultured with autologous CD4+T cells at a
ratio of 4:1 in 96-well round-bottomed plates for 24 h;
CD40L, CD28, and CD152 were then measured by flow
cytometry with the cells stained at 4°C for anti-CD40L,
anti-CD28, anti-CD152, and anti-CD4 antibodies.
Statistical analysis
All statistical analyses were conducted by SPSS 16.0 soft-
ware. Results were expressed as mean ± SD. Variables were
compared by Student’s t-test (data from different transfec-
tions were compared by paired t-test, others by two-group
t-test). Correlations were determined using Pearson’s cor-
relation coefficient. P < 0.05 was considered significant.
Additional files
Additional file 1: Supplementary tables on patient demographics
and medications and primers used for PCR. Table S1. Patient
demographics and medications. Table S2. Primers for PCR.
Additional file 2: Supplementary figures on the actual flow
cytometry profiles. Figure S1. represents for the actual flow cytometry
profiles of Figure 4A, B. Figure S2. represents for the actual flow
cytometry profiles of Figure 4C, D. Figure S3. represents for the actual
flow cytometry profiles of Figure 5D, E. Figure S4. represents for the
actual flow cytometry profiles of Figure 6D, E. Figure S5. represents for
the actual flow cytometry profiles of Figure 6F, G.
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